Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Starting two decades ago with the discoveries of genetic links between alpha-synuclein and
Parkinson's disease risk and the identification of aggregated alpha-synuclein as the main …

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for
Parkinson's disease (PD) and related synucleinopathies. They enable detection of seeding …

The clinicopathological heterogeneity in Lewy-body diseases (LBD) highlights the need for
pathology-driven biomarkers in-vivo. Misfolded alpha-synuclein (α-Syn) is a lead candidate …

Intracellular accumulation of abnormal proteins with conformational changes is the defining
neuropathological feature of neurodegenerative diseases. The pathogenic proteins that …

To address the need for more meaningful biomarkers of tauopathies, we have developed an
ultrasensitive tau seed amplification assay (4R RT-QuIC) for the 4-repeat (4R) tau …

Alzheimer disease (AD) and chronic traumatic encephalopathy (CTE) involve the abnormal
accumulation in the brain of filaments composed of both three-repeat (3R) and four-repeat …

The emergence of a novel class of infectious agent composed exclusively of a misfolded
protein (termed prions) has been a challenge in modern biomedicine. Despite similarities on …

It is difficult to distinguish Parkinson's disease (PD) in the early stage from those of various
disorders including atypical Parkinson's syndrome (APS), vascular parkinsonism (VP), and …

The inadvertent transmission of long incubating, untreatable and fatal neurodegenerative
prionopathies, notably iatrogenic Creutzfeldt–Jakob disease, following transplantation of …